Multimodality therapy for NSCLC

Keyphrases

• Chemotherapy 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Stage III Non-small Cell Lung Cancer 100%
• Combined Modality Therapy 100%
• Consolidation Therapy 50%
• Targeted Therapy 50%
• Induction Therapy 50%
• Radiotherapy 50%
• Patient Selection 50%
• Treatment Modalities 50%
• Erlotinib 50%
• Unselected Patients 50%
• Crizotinib 50%
• Checkpoint Inhibitors 50%
• Concurrent Use 50%
• Sequential Therapy 50%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Targeted Therapy 33%
• Erlotinib 33%
• Crizotinib 33%
• Radiation Therapy 33%
• Treatment Modality 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Chemotherapy 66%
• Erlotinib 33%
• Crizotinib 33%